Evidence map›Paper›PMID 24743895›Full record

ArticlePloS one2014

Silencing DACH1 promotes esophageal cancer growth by inhibiting TGF-β signaling.

Liang Wu, James G Herman, Malcolm V Brock, Kongming Wu, Gaoping Mao, Wenji Yan, Yan Nie, Hao Liang, Qimin Zhan, Wen Li and 1 more

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Article
  3. TheViruses · 2023
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Epigenetic heterogeneity in cancer.Biomarker research · 2019
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Liang WuDepartment of Gastroenterology & Hepatology, Chinese PLA General Hospital, Beijing, China.
James G HermanSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States of America.
Malcolm V BrockSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States of America.
Kongming WuTongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Gaoping MaoDepartment of Gastroenterology, General Air Force Hospital, Beijing, China.
Wenji YanDepartment of Gastroenterology & Hepatology, Chinese PLA General Hospital, Beijing, China.
Yan NieDepartment of Gastroenterology & Hepatology, The Affiliated Hainan Hospital of the Chinese PLA General Hospital, Hai Tang wan, Sanya, China.
Hao LiangDepartment of Gastroenterology & Hepatology, Chinese PLA General Hospital, Beijing, China.
Qimin ZhanState Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Wen LiDepartment of Gastroenterology & Hepatology, Chinese PLA General Hospital, Beijing, China.
Mingzhou GuoDepartment of Gastroenterology & Hepatology, Chinese PLA General Hospital, Beijing, China.

Funding

MIF in progression and treatment of ALDU01AA020821 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI NAGY, LAURA E. · 2012 to 2016
$2.1M
Corticostriatal networks and NMDAR mediation of habitual and flexible actionK22AA020303 · NIAAA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI BRIGMAN, JONATHAN L · 2011 to 2013
$486k
NIAAA NIH HHS K22 AA020303NIAAA NIH HHS U01 AA020821
6 · The paper itself

Abstract

Human Dachshund homologue 1 (DACH1) is a major component of the Retinal Determination Gene Network. Loss of DACH1 expression was found in breast, prostate, lung, endometrial, colorectal and hepatocellular carcinoma. To explore the expression, regulation and function of DACH1 in human esophageal cancer, 11 esophageal cancer cell lines, 10 cases of normal esophageal mucosa, 51 cases of different grades of dysplasia and 104 cases of primary esophageal squamous cancer were employed. Methylation specific PCR, immunohistochemistry, western blot, flow cytometry, small interfering RNAs, colony formation techniques and xenograft mice model were used. We found that DACH1 expression was regulated by promoter region hypermethylation in esophageal cancer cell lines. 18.8% (6 of 32) of grade 1, 42.1% (8 of 19) of grade 2 and grade 3 dysplasia (ED2,3), and 61.5% (64 of 104) of esophageal cancer were methylated, but no methylation was found in 10 cases of normal esophageal mucosa. The methylation was increased in progression tendency during esophageal carcinogenesis (P<0.01). DACH1 methylation was associated with poor differentiation (P<0.05) and late tumor stage (P<0.05). Restoration of DACH1 expression inhibited cell growth and activated TGF-β signaling in KYSE150 and KYSE510 cells. DACH1 suppressed human esophageal cancer cell tumor growth in xenograft mice. In conclusion, DACH1 is frequently methylated in human esophageal cancer and methylation of DACH1 is involved in the early stage of esophageal carcinogenesis. DACH1 expression is regulated by promoter region hypermethylation. DACH1 suppresses esophageal cancer growth by activating TGF-β signaling.

Indexed as

AnimalsBlotting, WesternCell SurvivalDNA MethylationEpigenesis, GeneticEsophageal NeoplasmsEye ProteinsFemaleFlow CytometryHumansImmunohistochemistryMicePromoter Regions, GeneticTranscription FactorsTransforming Growth Factor betaDACH1 protein, humanEye ProteinsTranscription FactorsTransforming Growth Factor beta

Identifiers

PMID24743895
PMCPMC3990688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.